Literature DB >> 23503777

[Renal denervation. Current developments].

A Saleh1.   

Abstract

UNLABELLED: METHODICAL INNOVATION: Renal denervation is a catheter-based, endovascular procedure for the treatment of drug-resistant hypertension. The aim of the therapy is to lower the blood pressure < 140/90 mmHg. PERFORMANCE: Even after successful minimally invasive therapy patients usually continue to take three or more antihypertensive drugs. Currently there is no evidence that renal denervation is a good option for the treatment of well-controlled hypertension in order to dispense with antihypertensive drugs. In carefully selected patients the mean reduction in systolic and diastolic blood pressure after renal denervation is 25-30 mmHg and 10-15 mmHg, respectively. ACHIEVEMENTS: Procedure-related or device-related complications are rare. Ablation catheters from different manufactures differ greatly in handling properties; however, up to now there is no evidence for relevant differences in safety and efficacy between the devices available.

Entities:  

Mesh:

Year:  2013        PMID: 23503777     DOI: 10.1007/s00117-012-2419-8

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  16 in total

1.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

Authors:  Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm
Journal:  Lancet       Date:  2010-11-17       Impact factor: 79.321

2.  Renal artery stenosis after renal sympathetic denervation.

Authors:  Benjamin Kaltenbach; Dani Id; Jennifer C Franke; Horst Sievert; Marcus Hennersdorf; Jens Maier; Stefan C Bertog
Journal:  J Am Coll Cardiol       Date:  2012-11-07       Impact factor: 24.094

3.  Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial.

Authors:  Murray D Esler; Henry Krum; Markus Schlaich; Roland E Schmieder; Michael Böhm; Paul A Sobotka
Journal:  Circulation       Date:  2012-12-18       Impact factor: 29.690

4.  Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.

Authors:  Alejandro de la Sierra; Julián Segura; José R Banegas; Manuel Gorostidi; Juan J de la Cruz; Pedro Armario; Anna Oliveras; Luis M Ruilope
Journal:  Hypertension       Date:  2011-03-28       Impact factor: 10.190

5.  [Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment].

Authors:  F Mahfoud; O Vonend; H Bruck; W Clasen; S Eckert; B Frye; H Haller; M Hausberg; U C Hoppe; J Hoyer; K Hahn; T Keller; B K Krämer; R Kreutz; S A Potthoff; H Reinecke; R Schmieder; V Schwenger; U Kintscher; M Böhm; L C Rump
Journal:  Dtsch Med Wochenschr       Date:  2011-11-02       Impact factor: 0.628

6.  Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease.

Authors:  Carmine Zoccali; Francesca Mallamaci; Saverio Parlongo; Sebastiano Cutrupi; Francesco Antonio Benedetto; Giovanni Tripepi; Graziella Bonanno; Francesco Rapisarda; Pasquale Fatuzzo; Giuseppe Seminara; Alessandro Cataliotti; Benedetta Stancanelli; Lorenzo Salvatore Malatino; Alessandro Cateliotti
Journal:  Circulation       Date:  2002-03-19       Impact factor: 29.690

7.  Low-renin status in therapy-resistant hypertension: a clue to efficient treatment.

Authors:  Ivar K Eide; Peter A Torjesen; Anders Drolsum; Almira Babovic; Nils P Lilledahl
Journal:  J Hypertens       Date:  2004-11       Impact factor: 4.844

8.  Relationship between central sympathetic activity and stages of human hypertension.

Authors:  Paul A Smith; Lee N Graham; Alan F Mackintosh; John B Stoker; David A S G Mary
Journal:  Am J Hypertens       Date:  2004-03       Impact factor: 2.689

9.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

10.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.